ractitioner's Docket No. MPI98-105P1RCP2DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Raju, Jeyaseelan

Application No.:

10/626,173

Group No.:

1652

Filed:

July 24, 2003

Examiner:

Monshipouri, Maryam

For: NOVEL CARK PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREFOR

Confirmation No. 1880

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL

- 1. Transmitted herewith for this application is/are:
 - a. This Transmittal (2 pages in duplicate);
 - b. Transmittal of Payment of Issue Fee (2 pages in duplicate);
 - c. Part B Fees Transmittal (1 page in duplicate);
 - d. Amendment After Allowance (7 pages);
 - e. Letter Accompanying Amendment After Allowance (2 pages);
 - f. Authorization to Act in a Representative Capacity for Mario Cloutier (2 pages);
 - g. Statement of Limited Recognition under 37 CFR § 11.9 (b) for Mario Cloutier (1 page); and
 - h. Return Postcard.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

TRANSMISSION

deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No.

□ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

Date: July 21, 2005 (type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Raju, Jeyaseelan		
Application No.:	10/626,173	Group No.:	1652
Filed:	July 24, 2003	Examiner:	Monshipouri, Maryam
For:	NOVEL CARK PROTEIN AND NUCLEIC ACID MOLECULES AND		
	USES THEREFOR		

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY

Dear Sir:

Date: _

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Mario Cloutier

Limited Recognition Under 37 CFR §11.9(b)

Customer Number 30405 or

Millennium Pharmaceuticals, Inc.

40 Landsdowne Street

Cambridge, MA 02139

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

July 21, 2005

as "Express Mail Post Office to Addressee"

Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

^{*}WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI98-105P1RCP2DV1M

FEE DEFICIENCY

- 3. Papers contained herein authorize payment of Issue Fees. It is believed no additional fees are required, however, if any additional extension and/or fee is required, charge Account No. 501668. If any additional fee for claims is required, charge Account No. 501668.
- 4. Correspondence Address
 Direct all future correspondence to:

Customer Number 30405 OR

Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

July 21, 2005

MILLENNIUM PHARMACEUTICALS, INC.

Βv

Mario Cloutier

Limited Recognition Under 37 C.F.R. §11.9(b)

40 Landsdowne Street Cambridge, MA 02139

Telephone - 617-577-3522

Facsimile - 617-551-8820

Practitioner's Docket No. MPI98-105P1RCP2DV1M

This is not a Power of Attorney to the above-named practitioner.

Accordingly, the practitioner named above does **not** have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.

Please continue to forward all written and telephonic communications to Jean M. Silveri at the address and telephone number listed below.

SIGNATURE of Practitioner of Record

	Respectfully submitted,
July 21, 2005	MILLENNIUM PHARMACEUTIC

By Jean M. Silveri

Registration No. 39,030

40 Landsdowne Street Cambridge, MA 02139 Telephone – (617) 679-7336 Facsimile – (617) 551-8820



BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR, 11.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: December 29, 2006

Harry I. Moatz

Director of Enrollment and Discipline

Date: July 21, 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	oplication cation No.:	f: Raju, Jeyaseelan 10/626,173	Group No.:	1652
Filed: For:		July 24, 2003 NOVEL CARK PROT THEREFOR	Examiner:	Monshipouri, Maryam ACID MOLECULES AND USES
			Confirmation No.: 1	880
Comm P.O. B	top Issue l dissioner fo ox 1450 dria, VA			
	LI	TTER ACCOMPANYIN (37 C	G AMENDMENT AFT .F.R. Section 1.312)	ER ALLOWANCE
1. Plea	se make th	e amendments shown in the	attached papers in this ap	plication in the
	(X) s ₁	ostract. pecification. rawings. aims.		
2.	Type of a	mendment:		·
		orrection of formal matters s shown in the remarks of the	e attached paper, these (are needed for proper disclosure of
	-	CERTIFICATION UND	ER 37 C.F.R. SECTIONS 1.	8(a) and 1.10*
I hereby	certify that, o	n the date shown below, this corre	espondence is being:	
X	Patents, P.C	ith the United States Postal Service. Box 1450, Alexandria, VA 223 F.R. SECTION 1.8(a)	13-1450.	Mail Stop Issue Fee, Commissioner for 37 C.F.R. SECTION 1.10*
X	with sufficient	ent postage as first class mail.		opress Mail Post Office to Addressee" ng Label No.
_	transmitted	by facsimile to the Patent and Trace	TRANSMISSION	

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Signature

Sean Hunziker

(type or print name of person certifying)

Practitioner's Docket No. MPI98-105P1RCP2DV1M

i

		protection of the invention and (2) require no substantial amount of additional work on the part of the PTO.	
	[]	Other (affects the disclosure, the scope of any claim or adds a claim) (M.P.E.P. Section 714.16, 7th ed.) As shown in the remarks in the attached supplemental page(s), there is stated the reason (1) why the amendment is needed, (2) why the proposed amended or new claims require no additional search or examination, (3) why the claims are patentable, and (4) why they were not earlier presented.	
3.	The issu	sue fee:	
	() (x) ()	has not been paid. is paid separately herewith. was paid on	
4.	Reques	t for Entry of Amendments:	
(a)	(X)	Because the issue fee has been paid or is paid herewith, the applicant hereby requests entry of the attached amendments. (37 C.F.R. Section 1.312).	
5.	Fees:		
	(X)	Please charge Account 501668 for any fees that may be required by the filing of this paper.	
July 21	, 2005	MILLENNIUM PHARMACEUTICALS, INC. By April Cloutier Mario Cloutier	
		Limited Recognition Under 37 C.F.R. §11.9(b)	

40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-577-3522 Facsimile - 617-551-8820